Cargando…

Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study

BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward...

Descripción completa

Detalles Bibliográficos
Autores principales: Bawor, Monica, Dennis, Brittany B., Tan, Charlie, Pare, Guillaume, Varenbut, Michael, Daiter, Jeff, Plater, Carolyn, Worster, Andrew, Marsh, David C., Steiner, Meir, Anglin, Rebecca, Desai, Dipika, Thabane, Lehana, Samaan, Zainab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672523/
https://www.ncbi.nlm.nih.gov/pubmed/26437921
http://dx.doi.org/10.1186/s13722-015-0040-7
_version_ 1782404585304883200
author Bawor, Monica
Dennis, Brittany B.
Tan, Charlie
Pare, Guillaume
Varenbut, Michael
Daiter, Jeff
Plater, Carolyn
Worster, Andrew
Marsh, David C.
Steiner, Meir
Anglin, Rebecca
Desai, Dipika
Thabane, Lehana
Samaan, Zainab
author_facet Bawor, Monica
Dennis, Brittany B.
Tan, Charlie
Pare, Guillaume
Varenbut, Michael
Daiter, Jeff
Plater, Carolyn
Worster, Andrew
Marsh, David C.
Steiner, Meir
Anglin, Rebecca
Desai, Dipika
Thabane, Lehana
Samaan, Zainab
author_sort Bawor, Monica
collection PubMed
description BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the effect of brain-derived neurotrophic factor (BDNF) and dopamine receptor D2 (DRD2) polymorphisms on continued opioid use among patients on methadone treatment for opioid use disorder. METHODS: BDNF 196G>A (rs6265) and DRD2-241A>G (rs1799978) genetic variants were examined in patients with opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We collected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens. RESULTS: Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent (n = 27) had at least one risk allele for rs6265 and rs1799978, respectively. These genetic variants were not significantly associated with continued opioid use while on methadone maintenance treatment [rs6265: odds ratio (OR) = 1.37, 95 % confidence interval (CI) = 0.792, 2.371, p = 0.264; rs1799978: OR 1.27, 95 % CI 0.511, 3.182, p = 0.603]. CONCLUSIONS: Despite an association of BDNFrs6265 and DRD2rs1799978 with addictive behaviors, these variants were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring further exploration. Additional research should focus on investigating these findings in larger samples and different populations.
format Online
Article
Text
id pubmed-4672523
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46725232015-12-09 Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study Bawor, Monica Dennis, Brittany B. Tan, Charlie Pare, Guillaume Varenbut, Michael Daiter, Jeff Plater, Carolyn Worster, Andrew Marsh, David C. Steiner, Meir Anglin, Rebecca Desai, Dipika Thabane, Lehana Samaan, Zainab Addict Sci Clin Pract Research BACKGROUND: The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood. The association between response to methadone treatment and genes that are involved in substance use behaviors and reward mechanisms is poorly understood, despite evidence suggesting their contribution to opioid use disorder. The aim of this study was to investigate the effect of brain-derived neurotrophic factor (BDNF) and dopamine receptor D2 (DRD2) polymorphisms on continued opioid use among patients on methadone treatment for opioid use disorder. METHODS: BDNF 196G>A (rs6265) and DRD2-241A>G (rs1799978) genetic variants were examined in patients with opioid use disorder who were recruited from methadone treatment clinics across Southern Ontario, Canada. We collected demographic information, substance use history, blood for genetic analysis, and urine to measure opioid use. We used regression analysis to examine the association between continued opioid use and genetic variants, adjusting for age, sex, ethnicity, methadone dose, duration in treatment, and number of urine screens. RESULTS: Among 240 patients treated with methadone for opioid use disorder, 36.3 percent (n = 87) and 11.3 percent (n = 27) had at least one risk allele for rs6265 and rs1799978, respectively. These genetic variants were not significantly associated with continued opioid use while on methadone maintenance treatment [rs6265: odds ratio (OR) = 1.37, 95 % confidence interval (CI) = 0.792, 2.371, p = 0.264; rs1799978: OR 1.27, 95 % CI 0.511, 3.182, p = 0.603]. CONCLUSIONS: Despite an association of BDNFrs6265 and DRD2rs1799978 with addictive behaviors, these variants were not associated with continued illicit opioid use in patients treated with methadone. Problematic use of opioids throughout treatment with methadone may be attributed to nongenetic factors or a polygenic effect requiring further exploration. Additional research should focus on investigating these findings in larger samples and different populations. BioMed Central 2015-10-06 2015 /pmc/articles/PMC4672523/ /pubmed/26437921 http://dx.doi.org/10.1186/s13722-015-0040-7 Text en © Bawor et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bawor, Monica
Dennis, Brittany B.
Tan, Charlie
Pare, Guillaume
Varenbut, Michael
Daiter, Jeff
Plater, Carolyn
Worster, Andrew
Marsh, David C.
Steiner, Meir
Anglin, Rebecca
Desai, Dipika
Thabane, Lehana
Samaan, Zainab
Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title_full Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title_fullStr Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title_full_unstemmed Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title_short Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
title_sort contribution of bdnf and drd2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672523/
https://www.ncbi.nlm.nih.gov/pubmed/26437921
http://dx.doi.org/10.1186/s13722-015-0040-7
work_keys_str_mv AT bawormonica contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT dennisbrittanyb contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT tancharlie contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT pareguillaume contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT varenbutmichael contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT daiterjeff contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT platercarolyn contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT worsterandrew contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT marshdavidc contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT steinermeir contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT anglinrebecca contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT desaidipika contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT thabanelehana contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy
AT samaanzainab contributionofbdnfanddrd2geneticpolymorphismstocontinuedopioiduseinpatientsreceivingmethadonetreatmentforopioidusedisorderanobservationalstudy